Guideline
Management of opioid use disorders: a national clinical practice guideline
Julie Bruneau, Keith Ahamad, Marie-Ève Goyer, Ginette Poulin, Peter Selby, Benedikt Fischer, T. Cameron Wild and Evan Wood; on behalf of the CIHR Canadian Research Initiative in Substance Misuse
CMAJ March 05, 2018 190 (9) E247-E257; DOI: https://doi.org/10.1503/cmaj.170958
Julie Bruneau
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MD MScKeith Ahamad
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MDMarie-Ève Goyer
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MD MScGinette Poulin
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MDPeter Selby
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MBBS MHScBenedikt Fischer
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
PhDT. Cameron Wild
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
PhDEvan Wood
Centre hospitalier de l’Université de Montréal (Bruneau), Université de Montréal; Département de médecine de famille et de médecine d’urgence (Bruneau, Goyer), Faculté de médecine, Université de Montréal, Montréal, Que.; British Columbia Centre on Substance Use (Ahamad), St. Paul’s Hospital; Department of Family Medicine (Ahamad), University of British Columbia, Vancouver, BC; Centre de recherche et d’aide pour narcomanes, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal (Goyer), Montréal, Que.; Addictions Foundation of Manitoba (Poulin); Max Rady College of Medicine, Postgraduate Medical Education (Poulin), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Addictions Division (Selby), Centre for Addiction and Mental Health; Department of Family and Community Medicine, Dalla Lana School of Public Health (Selby); Department of Psychiatry (Selby, Fischer), University of Toronto, Toronto, Ont.; Institute for Mental Health Policy Research (Fischer), Centre for Addiction and Mental Health, Toronto, Ont.; School of Public Health (Wild), Edmonton Clinic Health Academy, University of Alberta, Edmonton, Alta.; British Columbia Centre on Substance Use (Wood), St. Paul’s Hospital; Department of Medicine (Wood), University of British Columbia, Vancouver, BC
MD PhDData supplements
Earn CPD Credits
This article is eligible for 0.5 Mainpro+ credits.
Did you read this article?
Note: The YES link above may not work in certain versions of Internet Explorer 8. If you are having difficulties with this link, please try another browser.
English podcast
Baladodiffusion en français
Related Articles
- Donroe, J. H., & Tetrault, J. M. (2018). Narrowing the treatment gap in managing opioid use disorder. CMAJ, 190(9), E236-E237. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.180209.
- Rieb, L. M. (2018). Extended-release naltrexone overlooked in opioid use disorders guideline. CMAJ, 190(28), E862. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.69411.
- Randhawa, P. A., Brar, R., & Nolan, S. (2020). Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. CMAJ, 192(3), E73. Accessed April 19, 2024. https://doi.org/10.1503/cmaj.74018.
In this issue
Article tools
Management of opioid use disorders: a national clinical practice guideline
Julie Bruneau, Keith Ahamad, Marie-Ève Goyer, Ginette Poulin, Peter Selby, Benedikt Fischer, T. Cameron Wild, Evan Wood
CMAJ Mar 2018, 190 (9) E247-E257; DOI: 10.1503/cmaj.170958
Jump to section
Related Articles
Cited By...
- Recours aux opioides a action rapide pour soulager les symptomes de sevrage des opioides en milieu hospitalier
- Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario
- Using short-acting opioids to relieve opioid withdrawal in hospital
- Risk of opioid-related mortality associated with buprenorphine versus methadone: A systematic review of observational studies
- Association between sustained opioid prescription and frequent emergency department use: a cohort study
- Advancing virtual primary care for people with opioid use disorder (VPC OUD): a mixed-methods study protocol
- Is daily supervised buprenorphine-naloxone dosing necessary?
- Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis
- Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review
- "The idea is to help people achieve greater success and liberty": a qualitative study of expanded methadone take-home access in opioid use disorder treatment
- Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis
- Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
- Are patients goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder
- Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: Protocol for an open-label, parallel-group, superiority, randomized controlled trial
- Lignes directrices de pratique clinique pour les personnes sans-abri, logees precairement, ou ayant connu litinerance
- Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study
- Supervised consumption services for acute care hospital patients
- Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience
- Problems with hydromorphone prescribing as a response to the opioid crisis
- Use of a primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment for severe opioid use disorder: a case report
- Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North Americas increasingly potent illicit drug market
- Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis
- Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes
- The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations"
- Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
- Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews
- Managing opioid use disorder in primary care: PEER simplified guideline
- Prise en charge du trouble de consommation dopioides en premiere ligne: Lignes directrices simplifiees de PEER
- Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs
- Slow release oral morphine versus methadone for the treatment of opioid use disorder
- Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol
- Buprenorphine-naloxone
- Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review
- Patient engagement, treatment preferences and shared decision-making in the treatment of opioid use disorder in adults: a scoping review protocol
- Extended-release naltrexone overlooked in opioid use disorders guideline
- Narrowing the treatment gap in managing opioid use disorder
Podcast